Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 68 | 3,379 | 40% |
| 2020 | 57 | 3,119 | 43% |
| 2021 | 54 | 3,130 | 48% |
| 2022 | 54 | 3,009 | 52% |
| 2023 | 57 | 3,029 | 56% |
| 2024 | 56 | 3,414 | 59% |
| 2025 from claims | – | 3,419 3,137–3,617 | 61% |
| 2026 forecast | – | 3,557 3,129–4,104 | 62% |
| 2027 forecast | – | 3,685 3,150–4,391 | 62% |
| 2028 forecast | – | 3,816 3,184–4,672 | 63% |
| 2029 forecast | – | 3,949 3,225–4,952 | 64% |
| 2030 forecast | – | 4,083 3,271–5,233 | 65% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 47% of the cases CMS names in North Carolina; 29 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 15% inpatient hospital, 85% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~3,600 | ~510 | ~3,100 |
| 2027 · ~3,700 | ~510 | ~3,200 |
| 2028 · ~3,800 | ~510 | ~3,300 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 13% (15% in 2025), hospital outpatient about 87% (85% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 120 | 7,940+6.4%/yr | +6.4%/yr | 3.6 | 0% | 13,100 in 2030+8.7%/yr |
| Texas | 98 | 6,069+1.9%/yr | +1.9%/yr | 2.9 | 0% | 9,990 in 2030+8.7%/yr |
| Tennessee | 58 | 3,989+4.5%/yr | +4.5%/yr | 5.7 | 2% | 5,930 in 2030+6.8%/yr |
| Georgia | 43 | 2,875+5.7%/yr | +5.7%/yr | 3.4 | 0% | 5,590 in 2030+12%/yr |
| Virginia | 42 | 2,548+1.9%/yr | +1.9%/yr | 2.5 | 0% | 4,620 in 2030+10%/yr |
| Maryland | 33 | 2,509+4.4%/yr | +4.4%/yr | 2.9 | 1% | 3,560 in 2030+6%/yr |
| Kentucky | 40 | 2,343+2.3%/yr | +2.3%/yr | 5.2 | 0% | 4,370 in 2030+11%/yr |
| South Carolina | 29 | 1,874+3.7%/yr | +3.7%/yr | 2.8 | 0% | 3,150 in 2030+9%/yr |
| Mississippi | 20 | 1,240+1.2%/yr | +1.2%/yr | 3.3 | 0% | 1,510 in 2030+3.4%/yr |
| Louisiana | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.0 | 0% | 2,510 in 2030+13%/yr |
| Arkansas | 16 | 1,036−1.8%/yr | −1.8%/yr | 2.8 | 0% | 1,540 in 2030+6.9%/yr |
| Alabama | 19 | 1,031+1.9%/yr | +1.9%/yr | 2.4 | 0% | 1,640 in 2030+8%/yr |
| Oklahoma | 14 | 974+2.6%/yr | +2.6%/yr | 2.0 | 0% | 2,260 in 2030+15%/yr |
| Delaware | 12 | 798+6.5%/yr | +6.5%/yr | 4.7 | 0% | 1,560 in 2030+12%/yr |
| District of Columbia | 7 | 762+4.4%/yr | +4.4%/yr | 12.2 | 0% | 1,250 in 2030+8.6%/yr |
| West Virginia | 4 | 478−5.3%/yr | −5.3%/yr | 2.3 | 0% | 670 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 544 | 112,191−5.4%/yr | −5.4%/yr | 117.81.0× | 61% | 111,000 in 2030−0.2%/yr |
| ERCP & endoscopic ultrasound | 52 | 3,646−1.8%/yr | −1.8%/yr | 3.81.2× | 5% | 3,960 in 2030+1.4%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Capsovision leads with 50% of company spending on these surgeons in 2025, +49 pts on 2024.
In 2025, 22 companies reported engagement with North Carolina’s surgeons worth $196K in consulting, speaking, meals and travel tied to these products, about $3,509 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 31652 (bronch ebus samplng 1/2 node), commercial plans pay North Carolina’s hospitals a median of $3,677, from $3,677 at the lowest to $4,529 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.